What Caris Life Sciences's FY2025 10-K says: 12 signals
Caris Life Sciences filed its latest 10-K with the SEC on Mar 3, 2026. It discusses digital transformation, product launch and AI investment.
Public (CAI)Biotechnology Research1,001 to 5,000 employeescarislifesciences.comLinkedIn
- Filed
- Mar 3, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 9
What Caris Life Sciences's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Building business on platform leveraging NGS, AI/ML, and high-performance computing
AIMLNGShigh-performance computing
Caris's dataset grew to over 1,000,000 sequenced cases by end of 2025
The company's core competitive advantage is its massive, multi-modal clinico-genomic dataset, which requires significant, ongoing investment in data storage, management, security, and analytics infrastructure to process and monetize.
AIMLNGSWES
Planning to launch new blood-based detection solution, Caris Detect, in 2026
The upcoming launch of the Caris Detect assay is a major strategic initiative that will require significant investment in go-to-market activities, sales enablement, regulatory compliance, and the underlying technology infrastructure to support the new service at scale.
WGSAIML
Caris seeking NY CLEP approval to offer Caris Assure solution in New York.
The company's blood-based solution, Caris Assure, is currently unavailable in the key New York market, creating a revenue gap and a specific regulatory hurdle.
Expanding platform beyond oncology into cardiology, neurology, and metabolic conditions
WGS
Company leverages AI/ML and high-performance computing for its core molecular platform
Caris heavily relies on artificial intelligence, machine learning, and high-performance computing to analyze its vast datasets for drug discovery and diagnostics.
AIMLhigh-performance computingNGS
Utilizes cloud-computing architecture for massive scalability and real-time collaboration
The company's business model of analyzing massive biological datasets is fundamentally enabled by a scalable cloud architecture.
cloud-computing
Anticipates launch of Whole Genome Sequencing (WGS) solutions in 2026
The company is expanding its portfolio with the launch of WGS solutions, positioning itself as a leader in comprehensive sequencing and creating needs for advanced computational and data management infrastructure.
WGSWESWTS
Identifies 'Quantity Not Sufficient' (QNS) results as a key failure point in tissue profiling
The company highlights that insufficient tissue sample quality can lead to NGS test failure (QNS), a significant problem in diagnostics.
NGS
Showing 9 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Caris Life Sciences with the Signal API
One POST /v1/companies/enrich call with carislifesciences.com returns Caris Life Sciences 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"carislifesciences.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Caris Life Sciences 10-K
When did Caris Life Sciences file its latest 10-K?
What does Caris Life Sciences's latest 10-K say about platform strategy?
Where can I find Caris Life Sciences's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .